HNSCC
MCID: OBS525
MIFTS: 57

Obsolete: Squamous Cell Carcinoma of Head and Neck (HNSCC)

Categories: Cancer diseases, Rare diseases

Aliases & Classifications for Obsolete: Squamous Cell Carcinoma of Head and Neck

MalaCards integrated aliases for Obsolete: Squamous Cell Carcinoma of Head and Neck:

Name: Obsolete: Squamous Cell Carcinoma of Head and Neck 58
Head and Neck Squamous Cell Carcinoma 58
Hnscc 58

Characteristics:

Orphanet epidemiological data:

58
obsolete: squamous cell carcinoma of head and neck
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: All ages;

Classifications:



External Ids:

Orphanet 58 ORPHA67037

Summaries for Obsolete: Squamous Cell Carcinoma of Head and Neck

MalaCards based summary : Obsolete: Squamous Cell Carcinoma of Head and Neck, also known as head and neck squamous cell carcinoma, is related to oropharynx cancer and squamous cell papilloma. An important gene associated with Obsolete: Squamous Cell Carcinoma of Head and Neck is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha), and among its related pathways/superpathways are Signaling by GPCR and Apoptotic Pathways in Synovial Fibroblasts. The drugs Cevimeline and Raltitrexed have been mentioned in the context of this disorder. Affiliated tissues include lymph node, lung and t cells, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Obsolete: Squamous Cell Carcinoma of Head and Neck

Diseases related to Obsolete: Squamous Cell Carcinoma of Head and Neck via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 482)
# Related Disease Score Top Affiliating Genes
1 oropharynx cancer 31.9 TP53 PTEN PIK3CA HRAS EGFR
2 squamous cell papilloma 31.6 TP53 HRAS
3 papilloma 30.7 TP53 PTEN FGFR3 EGFR
4 breast squamous cell carcinoma 30.5 TP53 PIK3CA HRAS
5 in situ carcinoma 30.4 TP53 PTEN HRAS EGFR
6 soft tissue sarcoma 30.4 TP53 EGFR
7 acneiform dermatitis 30.4 HRAS EGFR
8 verrucous carcinoma 30.2 TP53 PTEN EGFR
9 skin melanoma 30.2 TP53 PTEN HRAS BRAF
10 retinitis pigmentosa 11 30.1 TP53 PTEN HRAS EGFR
11 lung benign neoplasm 30.1 TP53 HRAS EGFR
12 thymoma 30.1 TP53 PIK3CA HRAS EGFR
13 pleomorphic adenoma 30.1 TP53 HRAS CTNNB1
14 small cell carcinoma 29.9 TP53 PTEN EGFR
15 tongue cancer 29.9 TP53 PTEN EGFR CTNNB1
16 oral cavity cancer 29.9 TP53 TNFRSF10B PTEN PIK3CA EGFR
17 laryngeal squamous cell carcinoma 29.8 TP53 PTEN EGFR
18 thyroid tumor 29.8 TP53 PTEN PIK3CA HRAS BRAF
19 paronychia 29.7 HRAS EGFR
20 keratosis 29.7 TP53 PIK3CA HRAS FGFR3 EGFR
21 skin squamous cell carcinoma 29.6 TP53 PTEN HRAS EGFR BRAF
22 t-cell leukemia 29.6 TP53 SMAD4 PTEN PIK3CA HRAS
23 adenosquamous carcinoma 29.4 TP53 SMAD4 PTEN PIK3CA EGFR
24 gastrointestinal stromal tumor 29.4 TP53 PTEN FGFR3 EGFR BRAF
25 glioma 29.4 TP53 PTEN PIK3CA IDH2 EGFR BRAF
26 bladder cancer 29.4 TP53 PTEN PIK3CA HRAS FGFR3 EGFR
27 teratoma 29.3 TP53 PTEN FGFR3 CTNNB1
28 cervical squamous cell carcinoma 29.3 TP53 PIK3CA EGFR CTNNB1
29 malignant glioma 29.3 TP53 TNFRSF10B PTEN EGFR
30 leukemia, chronic lymphocytic 29.2 TP53 PTEN HRAS EGFR BRAF
31 thyroid carcinoma 29.2 TP53 PTEN PIK3CA HRAS CTNNB1 BRAF
32 tongue squamous cell carcinoma 29.0 TP53 PTEN EGFR CTNNB1
33 adenoma 29.0 TP53 SMAD4 PIK3CA GNAS CTNNB1 BRAF
34 leukemia, chronic myeloid 28.9 TP53 TNFRSF10B PTEN HRAS EGFR
35 glioma susceptibility 1 28.8 TP53 PTEN PIK3CA IDH2 HRAS EGFR
36 renal cell carcinoma, nonpapillary 28.6 TP53 TNFRSF10B PTEN PIK3CA HRAS EGFR
37 familial adenomatous polyposis 28.6 TP53 TNFRSF10B SMAD4 HRAS CTNNB1
38 esophageal cancer 28.6 TP53 SMAD4 PTEN PIK3CA HRAS EGFR
39 adenoid cystic carcinoma 28.5 TP53 PTEN PIK3CA HRAS EGFR CTNNB1
40 colorectal adenocarcinoma 28.5 TP53 PTEN HRAS EGFR CTNNB1 BRAF
41 colon adenocarcinoma 28.2 TP53 SMAD4 PTEN PIK3CA EGFR CTNNB1
42 squamous cell carcinoma, head and neck 28.2 TP53 TNFRSF10B SMAD4 PTEN PIK3CA NFE2L2
43 lung squamous cell carcinoma 28.1 TP53 PTEN PIK3CA NFE2L2 HRAS FGFR3
44 leukemia, acute myeloid 27.9 TP53 TNFRSF10B PTEN IDH2 HRAS EGFR
45 nasopharyngeal carcinoma 27.9 TP53 SMAD4 PTEN PIK3CA HRAS EGFR
46 glioblastoma multiforme 27.7 TP53 TNFRSF10B PTEN PIK3CA IDH2 HRAS
47 endometrial cancer 27.6 TP53 SMAD4 PTEN PIK3CA HRAS EGFR
48 gastric cancer 27.5 TP53 SMAD4 PTEN PIK3CA NFE2L2 HRAS
49 adenocarcinoma 27.4 TP53 SMAD4 PTEN PIK3CA HRAS GNAS
50 myeloma, multiple 27.3 TP53 TNFRSF10B PTEN IDH2 HRAS FGFR3

Graphical network of the top 20 diseases related to Obsolete: Squamous Cell Carcinoma of Head and Neck:



Diseases related to Obsolete: Squamous Cell Carcinoma of Head and Neck

Symptoms & Phenotypes for Obsolete: Squamous Cell Carcinoma of Head and Neck

GenomeRNAi Phenotypes related to Obsolete: Squamous Cell Carcinoma of Head and Neck according to GeneCards Suite gene sharing:

26 (show all 15)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.3 BRAF EGFR HRAS PIK3CA
2 Decreased viability GR00221-A-1 10.3 EGFR HRAS PIK3CA
3 Decreased viability GR00221-A-2 10.3 HRAS PIK3CA
4 Decreased viability GR00221-A-3 10.3 HRAS
5 Decreased viability GR00221-A-4 10.3 BRAF EGFR PIK3CA
6 Decreased viability GR00301-A 10.3 BRAF
7 Decreased viability GR00381-A-1 10.3 BRAF
8 Decreased viability GR00402-S-2 10.3 BRAF EGFR HRAS PIK3CA
9 Decreased viability in esophageal squamous lineage GR00235-A 10.03 BRAF CTNNB1 FGFR3 GNAS HRAS IDH2
10 Decreased cell migration GR00055-A-1 9.98 BRAF CTNNB1 EGFR FGFR3 HRAS MAP2K2
11 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.8 CTNNB1 EGFR FGFR3 HRAS PTEN
12 Increased cell death HMECs cells GR00103-A-0 9.63 CTNNB1 EGFR MAP2K2 PIK3CA PTEN TP53
13 Decreased sensitivity to paclitaxel GR00112-A-0 9.37 PTEN SMAD4
14 Increased cell migration GR00055-A-3 9.35 BRAF CTNNB1 EGFR HRAS PIK3CA
15 Reduced mammosphere formation GR00396-S 9.23 BRAF EGFR GNAS HRAS IDH2 NFE2L2

MGI Mouse Phenotypes related to Obsolete: Squamous Cell Carcinoma of Head and Neck:

45 (show all 28)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.41 BRAF CTNNB1 FGFR3 GNAS HRAS ING1
2 cardiovascular system MP:0005385 10.41 BRAF CTNNB1 EGFR GNAS HRAS IDH2
3 cellular MP:0005384 10.4 BRAF CTNNB1 EGFR FGFR3 GNAS ING1
4 growth/size/body region MP:0005378 10.4 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
5 homeostasis/metabolism MP:0005376 10.38 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
6 endocrine/exocrine gland MP:0005379 10.34 BRAF CTNNB1 EGFR GNAS HRAS ING1
7 integument MP:0010771 10.33 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
8 craniofacial MP:0005382 10.32 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
9 mortality/aging MP:0010768 10.32 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
10 neoplasm MP:0002006 10.32 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
11 digestive/alimentary MP:0005381 10.31 BRAF CTNNB1 EGFR FGFR3 HRAS MAP2K2
12 immune system MP:0005387 10.3 BRAF CTNNB1 EGFR FGFR3 GNAS ING1
13 hematopoietic system MP:0005397 10.27 BRAF CTNNB1 EGFR FGFR3 GNAS ING1
14 adipose tissue MP:0005375 10.24 BRAF EGFR GNAS MAP2K2 NFE2L2 PIK3CA
15 embryo MP:0005380 10.21 BRAF CTNNB1 EGFR NFE2L2 PIK3CA PTEN
16 nervous system MP:0003631 10.2 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
17 limbs/digits/tail MP:0005371 10.19 BRAF CTNNB1 EGFR FGFR3 GNAS IDH2
18 normal MP:0002873 10.14 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
19 hearing/vestibular/ear MP:0005377 10.13 BRAF CTNNB1 EGFR FGFR3 GNAS MAP2K2
20 liver/biliary system MP:0005370 10.13 BRAF CTNNB1 EGFR GNAS NFE2L2 PTEN
21 muscle MP:0005369 10.1 BRAF CTNNB1 EGFR GNAS PIK3CA PTEN
22 renal/urinary system MP:0005367 10.02 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
23 no phenotypic analysis MP:0003012 9.98 CTNNB1 EGFR FGFR3 GNAS HRAS PIK3CA
24 reproductive system MP:0005389 9.86 BRAF CTNNB1 EGFR FGFR3 PIK3CA PTEN
25 respiratory system MP:0005388 9.81 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
26 pigmentation MP:0001186 9.77 BRAF CTNNB1 EGFR PTEN TP53
27 skeleton MP:0005390 9.77 BRAF CTNNB1 EGFR FGFR3 GNAS HRAS
28 vision/eye MP:0005391 9.23 BRAF CTNNB1 EGFR FGFR3 MAP2K2 PIK3CA

Drugs & Therapeutics for Obsolete: Squamous Cell Carcinoma of Head and Neck

Drugs for Obsolete: Squamous Cell Carcinoma of Head and Neck (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 310)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cevimeline Approved Phase 4 107233-08-9 83898 25137844
2
Raltitrexed Approved, Investigational Phase 4 112887-68-0 104758
3 Muscarinic Agonists Phase 4
4 Cholinergic Agents Phase 4
5
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
6
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
7
Isotretinoin Approved Phase 3 4759-48-2 5538 5282379
8
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
9
Dapsone Approved, Investigational Phase 3 80-08-0 2955
10
Metformin Approved Phase 3 657-24-9 14219 4091
11
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
12
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
13
leucovorin Approved Phase 3 58-05-9 6006 143
14
Bevacizumab Approved, Investigational Phase 3 216974-75-3
15
Lenvatinib Approved, Investigational Phase 3 417716-92-8
16
Durvalumab Approved, Investigational Phase 3 1428935-60-7
17
afatinib Approved Phase 3 850140-72-6, 439081-18-2 10184653
18
Edetic Acid Approved, Vet_approved Phase 3 60-00-4, 62-33-9 6049
19
Pentetic acid Approved Phase 3 67-43-6
20
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
21
Melatonin Approved, Nutraceutical, Vet_approved Phase 3 73-31-4 896
22
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
23
Tirapazamine Investigational Phase 3 27314-97-2
24
Zalutumumab Investigational Phase 3 667901-13-5, 828933-61-3
25 Tocotrienol Investigational Phase 3 6829-55-6
26
Nimotuzumab Investigational Phase 3 780758-10-3, 828933-61-3
27 Nimorazole Investigational Phase 3 6506-37-2
28 Endostatins Phase 3 71581480
29 Protective Agents Phase 3
30 interferons Phase 3
31 Central Nervous System Depressants Phase 3
32 Antioxidants Phase 3
33 Interferon-alpha Phase 3
34 Antimalarials Phase 3
35 Antitubercular Agents Phase 3
36 Tocopherols Phase 3
37 Tocotrienols Phase 3
38 Deoxyglucose Phase 3
39 Hypoglycemic Agents Phase 3
40 Lugol's solution Phase 3
41 Antimitotic Agents Phase 3
42 Mitogens Phase 3
43 Folic Acid Antagonists Phase 3
44 Vitamin B Complex Phase 3
45 Folate Phase 3
46 Vitamin B9 Phase 3
47 Immunoglobulin G Phase 3
48 Endothelial Growth Factors Phase 3
49 Angiogenesis Inhibitors Phase 3
50 Pharmaceutical Solutions Phase 3

Interventional clinical trials:

(show top 50) (show all 626)
# Name Status NCT ID Phase Drugs
1 Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer Completed NCT03998696 Phase 4 Cisplatin 40 mg/m2;Cisplatin 100 mg/m2
2 An Investigator-Initiated,Multicenter,Randomized,Double-Blind Placebo-Controlled Design Study to Assess the Effectiveness of CeviMeline to Improve OraL Health in Patients With XErostomia Secondary to Radiation Therapy for Treatment of Head and Neck Squamous Cell Carcinoma Completed NCT00466388 Phase 4 Cevimeline
3 Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With Head and Neck Squamous Cell Carcinoma: a Prospective Randomized Controlled Trial Recruiting NCT03196843 Phase 4 Raltitrexed
4 Randomised Clinical Phase III Study of Radiotherapy Dose, Volume Evaluation for 3DCRT Versus IGRT and Analysis of Early Response in Head and Neck Squamous Cell Carcinoma Unknown status NCT01124409 Phase 3
5 DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification With Nimorazole During Radiotherapy/Chemoradiotherapy of Squamous Cell Carcinoma of the Head and Neck. Unknown status NCT02661152 Phase 3 Nimorazole
6 A Randomized, Open-label, Multi-center Phase III Study Designed to Evaluate the Safety and Efficacy of E10A in Patients With Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck Region Unknown status NCT02630264 Phase 3 Endostatins;Paclitaxel injection;Cisplatin injection
7 A Multi-centre Randomised Phase III Trial Comparing PET-CT Guided Watch and Wait Policy Versus Planned Neck Dissection for the Management of Locally Advanced (N2/N3) Nodal Metastases in Patients With Head and Neck Squamous Cancer Unknown status NCT00720070 Phase 3
8 A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy Completed NCT01345682 Phase 3 Afatinib;Methotrexate
9 Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma Completed NCT00158652 Phase 3 5FU, Paraplatin
10 A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
11 Phase III Randomized Trial of Concomitant Radiation, Cisplatin, and Tirapazamine Versus Concomitant Radiation and Cisplatin in Patients With Advanced Head and Neck Cancer Completed NCT00174837 Phase 3 Tirapazamine;Cisplatin
12 A Phase III Randomised, Stratified, Parallel-Group, Multi-Centre, Comparative Study of ZD1839 (Iressa®) 250 Mg and 500 Mg Versus Methotrexate for Previously Treated Patients With Squamous Cell Carcinoma of the Head and Neck Completed NCT00206219 Phase 3 Gefitinib;methotrexate
13 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck Completed NCT00193895 Phase 3 Carboplatin
14 DAHANCA 19: A Randomized Study of the Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Primary Curative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck Completed NCT00496652 Phase 3 Zalutumumab
15 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
16 Phase III Randomized Study of Adjuvant Biologic Therapy in Patients With Stages III/IV Head and Neck Squamous Cell Carcinoma Completed NCT00054561 Phase 3 isotretinoin
17 Neoadjuvant Docetaxel+Cisplatin and 5-fluorouracil (TPF) Followed by Radiotherapy+Concomitant Chemo or Cetuximab Versus Radiotherapy+Concomitant Chemo or Cetuximab in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Randomized Phase III Factorial Study. Completed NCT01086826 Phase 3 RT+CDDP/5-FU;RT+CETUXIMAB;INDUCTION CTx(TPF)+(RT+CDDP/5-FU);INDUCTION CTx(TPF)+(RT+CETUXIMAB)
18 Randomized, Double-blind, Multicenter Two-Stage Adaptive Phase 3 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin Versus the Chemotherapy Alone in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck Who Have Progressed on or After Prior Platinum-Based Chemotherapy Completed NCT01166542 Phase 3 Carboplatin;Paclitaxel;Placebo
19 Phase III Study Of Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients Completed NCT00201383 Phase 3 cisplatin
20 A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT Completed NCT01931150 Phase 3 Topical Dapsone 5% Gel;oral antibiotics
21 Effect of Melatonin in Combination With Neoadjuvant Chemotherapy to HIF-1⍺, CD44, CD133, and miR-210 Expression and Clinical Response in Locally Advanced Oral Squamous Cell Carcinoma (OSCC) Completed NCT04137627 Phase 3 Melatonin 20 MG Oral Capsule;Placebo oral capsule
22 Postoperative Radiation and Concurrent Chemotherapy With Weekly Docetaxel Versus Cisplatin in Patients With High Risk Squamous Cell Carcinoma of Head & Neck: a Randomized Multi-center Phase III Clinical Trial Recruiting NCT02923258 Phase 2, Phase 3 Docetaxel;Cisplatinum
23 A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Recruiting NCT04128696 Phase 3 GSK3359609;Pembrolizumab;Placebo
24 A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC) Recruiting NCT03765918 Phase 3 Cisplatin 100 mg/m^2
25 Multicenter Randomized Controlled Phase III Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy Recruiting NCT03700905 Phase 3 Neoadjuvant Nivolumab;Adjuvant Nivolumab;Adjuvant Nivolumab and Ipilimumab
26 Phase 3 Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Standard of Care for Locoregional Recurrent Head/Neck Squamous Cell Carcinoma in Patients Who Have Failed After at Least Two Lines of Therapy Recruiting NCT03769506 Phase 3 Physician's Choice SOC
27 A Phase 3, Randomized, Open-label Clinical Trial of Induction Chemotherapy Followed by Chemoradiotherapy Versus Chemoradiotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Recruiting NCT03815903 Phase 3 Induction chemotherapy
28 Randomized Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma Recruiting NCT03519048 Phase 3
29 Definitive Chemo-Radiotherapy With or Without Up-front Neck Dissection for Regionally Advanced Head and Neck Squamous Cell Carcinoma: A Phase III Multi-center Prospective Randomized Controlled Trial With Two Additional Observational Cohorts Recruiting NCT02918955 Phase 3 Chemotherapy (Cisplatin)
30 Multicenter, Randomized, Double-blind, Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of TQB2450 Plus Chemotherapy(Cisplatin or Carboplatin+ 5-Fluorouracil (5-FU) ) Versus Placebo Plus Chemotherapy as First-Line Treatment in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma(R/M SCCHN) Recruiting NCT03855384 Phase 3 TQB2450+cisplatin or carboplatin + 5-Fluorouracil (5-FU);placebo+cisplatin or carboplatin + 5-Fluorouracil (5-FU)
31 Uniform FDG‐PET Guided GRAdient Dose prEscription to Reduce Late Radiation Toxicity (UPGRADE‐RT): a Randomised Controlled Trial With Dose Reduction to the Elective Neck in Head and Neck Squamous Cell Carcinoma Recruiting NCT02442375 Phase 3
32 Phase III Trial of Laryngeal Preservation Comparing Induction Chemotherapy With Cisplatin, 5-fluorouracil and Docetaxel (TPF) Followed by Radiotherapy and Concomitant Administration of Radiotherapy With Cisplatin Recruiting NCT03340896 Phase 3 Docetaxel;Cisplatin;Fluorouracil
33 A Phase II/III Trial of Comparison of Benefit of Administration of Keytruda Via Artery or Fine Needle to Tumor Versus Vein for Immunotherapy of Advanced Solid Tumors Recruiting NCT03755739 Phase 2, Phase 3 Pembrolizumab
34 Phase III, Double-Blind, Placebo-Controlled Study of Post-Operative Adjuvant Concurrent Chemo-Radiotherapy With or Without Nimotuzumab for Stage III/IV Head & Neck Squamous Cell Cancer Recruiting NCT00957086 Phase 3 Nimotuzumab;Placebo
35 A Phase III Randomized Trial of Avelumab-cetuximab-Radiotherapy Versus Standards of Care in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Recruiting NCT02999087 Phase 3 Cetuximab;avelumab;Cisplatin
36 A Phase III Randomized Study of Chemo-radiotherapy Versus Radiotherapy Alone in the Adjuvant Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy) Recruiting NCT02998385 Phase 3 Cisplatin
37 Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions: A Randomized Clinical Trial (Part 1) Recruiting NCT03685409 Phase 3 Metformin Hydrochloride 500 MG;Placebo Oral Tablet
38 Non Inferiority Randomized Trial of Standard Radiotherapy Versus Hypofractionated Split Course Radiotherapy in Elderly Vulnerable Patients With Inoperable Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT01864850 Phase 3
39 A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) Active, not recruiting NCT03358472 Phase 3 Pembrolizumab;Epacadostat;Cetuximab;Cisplatin;Carboplatin;5-Fluorouracil
40 A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412) Active, not recruiting NCT03040999 Phase 3 Placebo;Cisplatin
41 A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab) Active, not recruiting NCT01950689 Phase 3 Nimorazole
42 A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT02358031 Phase 3 Cisplatin;Carboplatin;5-FU
43 A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy. Active, not recruiting NCT01856478 Phase 3 methotrexate;afatinib
44 A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02 Active, not recruiting NCT01427478 Phase 3 AFATINIB;Placebo of AFATINIB
45 A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
46 Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00158678 Phase 3 concomitant cisplatin
47 Randomized Trial of Concomitant Chemotherapy in Patients With Locally Advanced HNSCC Treated by Radiotherapy-erbitux Active, not recruiting NCT00609284 Phase 3 cetuximab;Carboplatin, 5FU concomitant
48 Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation Active, not recruiting NCT01884623 Phase 3 Cetuximab;Methotrexate
49 A Phase III Randomized Trial of MK-3475 (Pembrolizumab) Versus Standard Treatment in Subjects With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT02252042 Phase 3 methotrexate;docetaxel
50 Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin Active, not recruiting NCT00999700 Phase 3 docetaxel - cisplatin - 5-fluorouracil;cetuximab;cisplatin

Search NIH Clinical Center for Obsolete: Squamous Cell Carcinoma of Head and Neck

Genetic Tests for Obsolete: Squamous Cell Carcinoma of Head and Neck

Anatomical Context for Obsolete: Squamous Cell Carcinoma of Head and Neck

MalaCards organs/tissues related to Obsolete: Squamous Cell Carcinoma of Head and Neck:

40
Lymph Node, Lung, T Cells, Breast, Endothelial, Tongue, Thyroid

Publications for Obsolete: Squamous Cell Carcinoma of Head and Neck

Articles related to Obsolete: Squamous Cell Carcinoma of Head and Neck:

(show top 50) (show all 7626)
# Title Authors PMID Year
1
Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10. 61 6
11801303 2002
2
Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. 6
10866301 2000
3
Rare loss-of-function mutation of a death receptor gene in head and neck cancer. 6
9721851 1998
4
R2TP/PAQosome as a promising chemotherapeutic target in cancer. 61
31890057 2020
5
Nerve growth factor (NGF)-TrkA axis in head and neck squamous cell carcinoma triggers EMT and confers resistance to the EGFR inhibitor erlotinib. 61
31838083 2020
6
Incidence of Micrometastasis and Isolated Tumour Cells in Clinicopathologically Node-Negative Head and Neck Squamous Cell Carcinoma. 61
31988576 2020
7
STAT1 inhibits T-cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma. 61
31709529 2020
8
A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma. 61
31678634 2020
9
Radiosensitization approaches for HPV-positive and HPV-negative head and neck squamous carcinomas. 61
31283004 2020
10
Development and Validation of a Novel and Rapid Molecular Detection Method for High-Risk Human Papillomavirus in Formalin-Fixed, Paraffin-Embedded Tumor Tissue. 61
31837430 2020
11
Spleen tyrosine kinase expression is correlated with human papillomavirus in head and neck cancer. 61
31864959 2020
12
CXCL11-CXCR3 axis mediates tumor lymphatic crosstalk and inflammation induced tumor promoting pathways in head and neck cancers. 61
32035061 2020
13
Patterns of protein expression in human head and neck cancer cell lines differ after proton vs photon radiotherapy. 61
31710172 2020
14
Tumor immune microenvironment in head and neck cancers. 61
32017286 2020
15
Immunotherapy orchestrates radiotherapy in composing abscopal effects: A strategic review in metastatic head and neck cancer. 61
31834023 2020
16
Radiotherapy for geriatric head-and-neck cancer patients: what is the value of standard treatment in the elderly? 61
32019576 2020
17
Assessment of the cytotoxic effects of aporphine prototypes on head and neck cancer cells. 61
31102120 2020
18
Lipidome-based rapid diagnosis with machine learning for detection of TGF-β signalling activated area in head and neck cancer. 61
32020064 2020
19
KIR2DS4, KIR2DL2, and KIR2DS4del are linked with basaloid tumors, lymph node metastasis, advanced stage and metastatic risk in head and neck squamous cell carcinoma. 61
31751561 2020
20
Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma. 61
31864957 2020
21
Transfer RNA methyltransferase gene NSUN2 mRNA expression modifies the effect of T cell activation score on patient survival in head and neck squamous carcinoma. 61
31887619 2020
22
The impact of diabetes in head and neck cancer. 61
32022731 2020
23
Involvement of the TGF-β1 pathway in caveolin-1-associated regulation of head and neck tumor cell metastasis. 61
31966060 2020
24
MT4-MMP promotes invadopodia formation and cell motility in FaDu head and neck cancer cells. 61
31813546 2020
25
Targeting CMTM6 Suppresses Stem Cell-Like Properties and Enhances Antitumor Immunity in Head and Neck Squamous Cell Carcinoma. 61
31771985 2020
26
A novel splice variant of LOXL2 promotes progression of human papillomavirus-negative head and neck squamous cell carcinoma. 61
31721164 2020
27
Prognostic capacity of Systemic Inflammation Response Index (SIRI) in patients with head and neck squamous cell carcinoma. 61
31750591 2020
28
Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma. 61
31771883 2020
29
Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition. 61
32020377 2020
30
Overall assessment of tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma: time to take notice. 61
32022615 2020
31
Pretreatment ADC is not a prognostic factor for local recurrences in head and neck squamous cell carcinoma when clinical T-stage is known. 61
31529258 2020
32
Somatic mitochondrial mutation discovery using ultra-deep sequencing of the mitochondrial genome reveals spatial tumor heterogeneity in head and neck squamous cell carcinoma. 61
31830557 2020
33
Second-look PET-CT following an initial incomplete PET-CT response to (chemo)radiotherapy for head and neck squamous cell carcinoma. 61
31485835 2020
34
Effect of Small-molecule Tyrosine Kinase Inhibitors on PDGF-AA/BB and PDGFRα/β Expression in SCC According to HPV16 Status. 61
32014925 2020
35
Safety of Prophylactic Gastrostomy Tube Placement and Gastrostomy Tube Usage in Patients Treated by Radio(chemo)therapy for Head and Neck Cancer. 61
32014970 2020
36
EGFR enhances the stemness and progression of oral cancer through inhibiting autophagic degradation of SOX2. 61
31823521 2020
37
Influence of tumour necrosis factor alpha on epithelial-mesenchymal transition of oral cancer cells in co-culture with mesenchymal stromal cells. 61
31345665 2020
38
Identification of new hypoxia-regulated epithelial-mesenchymal transition marker genes labeled by H3K4 acetylation. 61
31408253 2020
39
The cox-filter method identifies respective subtype-specific lncRNA prognostic signatures for two human cancers. 61
32024523 2020
40
Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. 61
31863963 2020
41
Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. 61
31744898 2020
42
Diclofenac Mouthwash as a potential therapy for reducing pain and discomfort in chemo-radiotherapy-induced oral mucositis. 61
32017243 2020
43
Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma. 61
31128940 2020
44
The critical effects of matrices on cultured carcinoma cells: Human tumor-derived matrix promotes cell invasive properties. 61
32017929 2020
45
Prognostic significance of MTOR expression in HPV positive and negative head and neck cancers treated by chemoradiation. 61
31657099 2020
46
A proposal for classification of oropharyngeal squamous cell carcinoma: Morphology and status of HPV by immunohistochemistry and molecular biology. 61
31465605 2020
47
PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer. 61
31785230 2020
48
Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma. 61
32035695 2020
49
DKK3 expression and function in head and neck squamous cell carcinoma and other cancers. 61
32032750 2020
50
Prognostic significance of venous invasion in node-negative head and neck squamous cell carcinoma. 61
31732985 2020

Variations for Obsolete: Squamous Cell Carcinoma of Head and Neck

ClinVar genetic disease variations for Obsolete: Squamous Cell Carcinoma of Head and Neck:

6 (show top 50) (show all 383) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 EGFR NM_005228.5(EGFR):c.2155G>C (p.Gly719Arg)SNV Likely pathogenic,drug response 45224 rs28929495 7:55241707-55241707 7:55174014-55174014
2 TP53 NM_000546.5(TP53):c.832C>A (p.Pro278Thr)SNV Likely pathogenic,drug response 376643 rs17849781 17:7577106-7577106 17:7673788-7673788
3 TP53 NM_000546.5(TP53):c.537T>G (p.His179Gln)SNV Pathogenic 376607 rs876660821 17:7578393-7578393 17:7675075-7675075
4 TP53 NM_000546.5(TP53):c.578A>C (p.His193Pro)SNV Pathogenic 376612 rs786201838 17:7578271-7578271 17:7674953-7674953
5 TP53 NM_000546.5(TP53):c.713G>T (p.Cys238Phe)SNV Pathogenic 376574 rs730882005 17:7577568-7577568 17:7674250-7674250
6 TP53 NM_000546.5(TP53):c.712T>C (p.Cys238Arg)SNV Pathogenic 376576 rs1057519981 17:7577569-7577569 17:7674251-7674251
7 TP53 NM_000546.5(TP53):c.841G>T (p.Asp281Tyr)SNV Pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
8 TP53 NM_000546.5(TP53):c.841G>A (p.Asp281Asn)SNV Pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
9 PIK3CA NM_006218.4(PIK3CA):c.1357G>A (p.Glu453Lys)SNV Pathogenic 376470 rs1057519925 3:178928079-178928079 3:179210291-179210291
10 PIK3CA NM_006218.4(PIK3CA):c.2176G>A (p.Glu726Lys)SNV Pathogenic 376476 rs867262025 3:178938934-178938934 3:179221146-179221146
11 PIK3CA NM_006218.4(PIK3CA):c.1637A>G (p.Gln546Arg)SNV Pathogenic 45466 rs397517201 3:178936095-178936095 3:179218307-179218307
12 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
13 TP53 NM_000546.5(TP53):c.659A>G (p.Tyr220Cys)SNV Pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
14 TP53 NM_000546.5(TP53):c.488A>G (p.Tyr163Cys)SNV Pathogenic 127814 rs148924904 17:7578442-7578442 17:7675124-7675124
15 TP53 NM_000546.5(TP53):c.422G>A (p.Cys141Tyr)SNV Pathogenic 140801 rs587781288 17:7578508-7578508 17:7675190-7675190
16 TP53 NM_000546.5(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
17 TP53 NM_000546.5(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
18 TP53 NM_000546.5(TP53):c.842A>G (p.Asp281Gly)SNV Pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
19 TP53 NM_000546.5(TP53):c.706T>G (p.Tyr236Asp)SNV Pathogenic 142183 rs587782289 17:7577575-7577575 17:7674257-7674257
20 TP53 NM_000546.5(TP53):c.833C>T (p.Pro278Leu)SNV Pathogenic 232497 rs876659802 17:7577105-7577105 17:7673787-7673787
21 TP53 NM_000546.5(TP53):c.743G>T (p.Arg248Leu)SNV Pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
22 PTEN NM_001304718.2(PTEN):c.-363C>GSNV Pathogenic 375958 rs121909224 10:89692904-89692904 10:87933147-87933147
23 TP53 NM_000546.5(TP53):c.856G>A (p.Glu286Lys)SNV Pathogenic 183752 rs786201059 17:7577082-7577082 17:7673764-7673764
24 TNFRSF10B TNFRSF10B, 2-BP INSinsertion Pathogenic 6194
25 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln)SNV Pathogenic 7829 rs121909229 10:89692905-89692905 10:87933148-87933148
26 PTEN NM_001304718.2(PTEN):c.-389C>GSNV Pathogenic 7842 rs121909237 10:89692878-89692878 10:87933121-87933121
27 ING1 NM_198219.3(ING1):c.644G>C (p.Cys215Ser)SNV Pathogenic 8067 rs121909250 13:111372083-111372083 13:110719736-110719736
28 ING1 NM_198219.3(ING1):c.647A>G (p.Asn216Ser)SNV Pathogenic 8068 rs121909251 13:111372086-111372086 13:110719739-110719739
29 ING1 NM_198219.3(ING1):c.575C>A (p.Ala192Asp)SNV Pathogenic 8069 rs121909252 13:111372014-111372014 13:110719667-110719667
30 MAP2K2 NM_030662.3(MAP2K2):c.169T>G (p.Phe57Val)SNV Pathogenic 8273 rs121434498 19:4117551-4117551 19:4117553-4117553
31 SMAD4 NM_005359.5(SMAD4):c.1081C>T (p.Arg361Cys)SNV Pathogenic 8543 rs80338963 18:48591918-48591918 18:51065548-51065548
32 TP53 NM_000546.5(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
33 TP53 NM_000546.5(TP53):c.733G>T (p.Gly245Cys)SNV Pathogenic 12349 rs28934575 17:7577548-7577548 17:7674230-7674230
34 TP53 NM_000546.5(TP53):c.725G>A (p.Cys242Tyr)SNV Pathogenic 12354 rs121912655 17:7577556-7577556 17:7674238-7674238
35 TP53 NM_000546.5(TP53):c.584T>C (p.Ile195Thr)SNV Pathogenic 216077 rs760043106 17:7578265-7578265 17:7674947-7674947
36 TP53 NM_000546.5(TP53):c.517G>A (p.Val173Met)SNV Pathogenic 233951 rs876660754 17:7578413-7578413 17:7675095-7675095
37 TP53 NM_000546.5(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
38 TP53 NM_000546.5(TP53):c.1010G>A (p.Arg337His)SNV Pathogenic 12379 rs121912664 17:7574017-7574017 17:7670699-7670699
39 TP53 NM_000546.5(TP53):c.659A>C (p.Tyr220Ser)SNV Pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
40 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
41 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
42 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys)SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
43 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
44 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
45 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
46 TP53 NM_000546.5(TP53):c.733G>A (p.Gly245Ser)SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
47 TP53 NM_000546.5(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
48 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
49 BRAF NM_004333.6(BRAF):c.1799T>A (p.Val600Glu)SNV Pathogenic 13961 rs113488022 7:140453136-140453136 7:140753336-140753336
50 BRAF NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly)SNV Pathogenic 13972 rs121913338 7:140453154-140453154 7:140753354-140753354

Expression for Obsolete: Squamous Cell Carcinoma of Head and Neck

Search GEO for disease gene expression data for Obsolete: Squamous Cell Carcinoma of Head and Neck.

Pathways for Obsolete: Squamous Cell Carcinoma of Head and Neck

Pathways related to Obsolete: Squamous Cell Carcinoma of Head and Neck according to GeneCards Suite gene sharing:

(show top 50) (show all 145)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.22 TP53 TNFRSF10B SMAD4 PTEN PIK3CA MAP2K2
2
Show member pathways
13.91 TP53 TNFRSF10B PTEN MAP2K2 HRAS GNAS
3
Show member pathways
13.87 TP53 TNFRSF10B SMAD4 PTEN MAP2K2 HRAS
4
Show member pathways
13.77 SMAD4 PIK3CA MAP2K2 HRAS FGFR3 EGFR
5
Show member pathways
13.77 TP53 SMAD4 MAP2K2 HRAS GNAS FGFR3
6
Show member pathways
13.75 TP53 TNFRSF10B SMAD4 MAP2K2 HRAS GNAS
7
Show member pathways
13.64 SMAD4 MAP2K2 HRAS GNAS FGFR3 EGFR
8
Show member pathways
13.61 TP53 TNFRSF10B SMAD4 PIK3CA MAP2K2 HRAS
9
Show member pathways
13.58 SMAD4 PIK3CA MAP2K2 HRAS FGFR3 EGFR
10
Show member pathways
13.48 TP53 TNFRSF10B PTEN HRAS GNAS FGFR3
11
Show member pathways
13.48 PTEN PIK3CA MAP2K2 HRAS GNAS EGFR
12
Show member pathways
13.44 TP53 PIK3CA MAP2K2 HRAS FGFR3 EGFR
13
Show member pathways
13.38 TNFRSF10B SMAD4 PTEN HRAS FGFR3 EGFR
14
Show member pathways
13.37 PTEN MAP2K2 HRAS GNAS FGFR3 EGFR
15
Show member pathways
13.36 MAP2K2 HRAS GNAS FGFR3 EGFR CTNNB1
16
Show member pathways
13.3 TP53 PTEN MAP2K2 HRAS GNAS EGFR
17
Show member pathways
13.21 TP53 SMAD4 PIK3CA MAP2K2 HRAS GNAS
18
Show member pathways
13.15 TP53 PTEN MAP2K2 HRAS GNAS FGFR3
19
Show member pathways
13.12 MAP2K2 HRAS GNAS EGFR CTNNB1 BRAF
20
Show member pathways
13.08 TP53 MAP2K2 HRAS GNAS CTNNB1 BRAF
21
Show member pathways
13.04 TP53 PIK3CA MAP2K2 HRAS GNAS EGFR
22
Show member pathways
13.04 TP53 TNFRSF10B PTEN PIK3CA MAP2K2 HRAS
23
Show member pathways
13.04 TP53 PTEN PIK3CA MAP2K2 HRAS GNAS
24
Show member pathways
13 PTEN PIK3CA MAP2K2 HRAS EGFR BRAF
25
Show member pathways
13 PTEN PIK3CA MAP2K2 HRAS EGFR CTNNB1
26
Show member pathways
12.99 MAP2K2 HRAS GNAS EGFR CTNNB1 BRAF
27
Show member pathways
12.98 PTEN MAP2K2 HRAS CTNNB1 BRAF
28
Show member pathways
12.98 PTEN PIK3CA MAP2K2 HRAS GNAS FGFR3
29
Show member pathways
12.93 PIK3CA MAP2K2 HRAS EGFR BRAF
30
Show member pathways
12.9 TP53 TNFRSF10B PIK3CA MAP2K2 HRAS
31
Show member pathways
12.89 MAP2K2 HRAS GNAS CTNNB1 BRAF
32
Show member pathways
12.88 TP53 SMAD4 PTEN PIK3CA MAP2K2 HRAS
33
Show member pathways
12.86 PTEN PIK3CA MAP2K2 HRAS BRAF
34 12.86 TP53 MAP2K2 HRAS FGFR3 EGFR BRAF
35
Show member pathways
12.83 TP53 PTEN PIK3CA HRAS FGFR3 EGFR
36
Show member pathways
12.83 PIK3CA MAP2K2 HRAS GNAS FGFR3 EGFR
37
Show member pathways
12.82 TP53 PTEN PIK3CA MAP2K2 HRAS CTNNB1
38
Show member pathways
12.77 PIK3CA MAP2K2 HRAS GNAS EGFR
39
Show member pathways
12.77 MAP2K2 HRAS GNAS EGFR BRAF
40
Show member pathways
12.76 TP53 MAP2K2 HRAS EGFR BRAF
41
Show member pathways
12.76 PIK3CA MAP2K2 HRAS GNAS EGFR CTNNB1
42 12.75 PIK3CA MAP2K2 HRAS FGFR3 EGFR BRAF
43
Show member pathways
12.72 TP53 PTEN PIK3CA MAP2K2 HRAS GNAS
44
Show member pathways
12.7 PTEN PIK3CA MAP2K2 HRAS EGFR
45
Show member pathways
12.69 TP53 PIK3CA HRAS EGFR CTNNB1
46
Show member pathways
12.67 PIK3CA MAP2K2 HRAS GNAS EGFR
47 12.65 TP53 PTEN PIK3CA MAP2K2 HRAS FGFR3
48
Show member pathways
12.65 TP53 PTEN PIK3CA MAP2K2 HRAS FGFR3
49
Show member pathways
12.64 PTEN PIK3CA MAP2K2 HRAS
50
Show member pathways
12.62 PIK3CA HRAS FGFR3 BRAF

GO Terms for Obsolete: Squamous Cell Carcinoma of Head and Neck

Cellular components related to Obsolete: Squamous Cell Carcinoma of Head and Neck according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.93 TP53 SMAD4 PTEN NFE2L2 MAP2K2 ING1
2 cytoplasm GO:0005737 9.73 TP53 SMAD4 PTEN PIK3CA NFE2L2 MAP2K2
3 perinuclear region of cytoplasm GO:0048471 9.65 MAP2K2 HRAS GNAS EGFR CTNNB1
4 cytosol GO:0005829 9.36 TP53 SMAD4 PTEN PIK3CA NFE2L2 MAP2K2

Biological processes related to Obsolete: Squamous Cell Carcinoma of Head and Neck according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.09 TP53 SMAD4 NFE2L2 HRAS EGFR CTNNB1
2 phosphorylation GO:0016310 10.03 PIK3CA MAP2K2 FGFR3 EGFR BRAF
3 apoptotic process GO:0006915 10.03 TP53 TNFRSF10B PTEN HRAS FGFR3
4 protein phosphorylation GO:0006468 10 PIK3CA MAP2K2 FGFR3 EGFR BRAF
5 negative regulation of apoptotic process GO:0043066 9.97 TP53 PTEN EGFR CTNNB1 BRAF
6 positive regulation of cell proliferation GO:0008284 9.97 PTEN HRAS FGFR3 EGFR CTNNB1
7 response to drug GO:0042493 9.91 TP53 PTEN GNAS CTNNB1
8 positive regulation of gene expression GO:0010628 9.91 TP53 PTEN NFE2L2 HRAS CTNNB1 BRAF
9 negative regulation of gene expression GO:0010629 9.89 TP53 MAP2K2 HRAS CTNNB1
10 heart development GO:0007507 9.88 TP53 PTEN MAP2K2 CTNNB1
11 MAPK cascade GO:0000165 9.88 MAP2K2 HRAS FGFR3 EGFR BRAF
12 cell proliferation GO:0008283 9.85 TP53 SMAD4 PTEN EGFR CTNNB1
13 negative regulation of cell proliferation GO:0008285 9.85 TP53 SMAD4 PTEN ING1 HRAS CTNNB1
14 positive regulation of MAPK cascade GO:0043410 9.81 HRAS FGFR3 CTNNB1
15 response to estradiol GO:0032355 9.8 PTEN EGFR CTNNB1
16 peptidyl-tyrosine phosphorylation GO:0018108 9.8 MAP2K2 FGFR3 EGFR BRAF
17 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.8 PTEN HRAS FGFR3 EGFR BRAF
18 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.77 PIK3CA EGFR BRAF
19 regulation of cell proliferation GO:0042127 9.72 TP53 SMAD4 EGFR CTNNB1 BRAF
20 positive regulation of transcription, DNA-templated GO:0045893 9.7 TP53 SMAD4 NFE2L2 MAP2K2 ING1 EGFR
21 thymus development GO:0048538 9.69 MAP2K2 CTNNB1 BRAF
22 positive regulation of histone H3-K4 methylation GO:0051571 9.64 SMAD4 CTNNB1
23 trachea formation GO:0060440 9.56 MAP2K2 CTNNB1
24 cellular response to drug GO:0035690 9.56 TP53 NFE2L2 EGFR BRAF
25 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.55 TP53 NFE2L2
26 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.54 TP53 NFE2L2
27 hair follicle placode formation GO:0060789 9.52 GNAS CTNNB1
28 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.13 TP53 MAP2K2 EGFR
29 regulation of axon regeneration GO:0048679 8.8 PTEN MAP2K2 BRAF

Molecular functions related to Obsolete: Squamous Cell Carcinoma of Head and Neck according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.32 TP53 TNFRSF10B SMAD4 PTEN PIK3CA NFE2L2
2 identical protein binding GO:0042802 9.91 TP53 SMAD4 PTEN FGFR3 EGFR BRAF
3 kinase activity GO:0016301 9.85 PIK3CA MAP2K2 FGFR3 EGFR BRAF
4 protein phosphatase binding GO:0019903 9.54 TP53 EGFR CTNNB1
5 RNA polymerase II transcription factor binding GO:0001085 9.43 TP53 SMAD4 CTNNB1
6 I-SMAD binding GO:0070411 9.4 SMAD4 CTNNB1
7 nucleotide binding GO:0000166 9.35 MAP2K2 HRAS FGFR3 EGFR BRAF
8 RNA polymerase II activating transcription factor binding GO:0001102 9.33 TP53 NFE2L2 CTNNB1
9 transcription cofactor binding GO:0001221 9.32 TP53 NFE2L2
10 protein tyrosine kinase activity GO:0004713 8.92 MAP2K2 FGFR3 EGFR BRAF

Sources for Obsolete: Squamous Cell Carcinoma of Head and Neck

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....